These highly concentrated evolutionary venations indicate scholars’ continuous and steady focus on NSCLC, CML, renal cell carcinoma, chronic lymphocytic leukemia, etc. These different evolutionary lines show a clear development path: TKIs research is disease focused and revolved around “gene targets/targeted drugs/resistance mechanisms.” For example, in the CML venation, investigators focused on the BRC-ABL in 2016 and on dasatinib and nilotinib in 2017-2020, which could both target BCR-ABL and overcome imatinib resistance [72,73]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.